Published in Neuropathol Appl Neurobiol on February 19, 2010
ALS/FTD Mutation-Induced Phase Transition of FUS Liquid Droplets and Reversible Hydrogels into Irreversible Hydrogels Impairs RNP Granule Function. Neuron (2015) 2.63
Distinct brain transcriptome profiles in C9orf72-associated and sporadic ALS. Nat Neurosci (2015) 2.42
An ALS-associated mutation affecting TDP-43 enhances protein aggregation, fibril formation and neurotoxicity. Nat Struct Mol Biol (2011) 1.58
TDP-43-mediated neuron loss in vivo requires RNA-binding activity. PLoS One (2010) 1.58
Neurodegeneration the RNA way. Prog Neurobiol (2011) 1.43
Phosphorylation promotes neurotoxicity in a Caenorhabditis elegans model of TDP-43 proteinopathy. J Neurosci (2010) 1.41
Hippocampal sclerosis of aging, a prevalent and high-morbidity brain disease. Acta Neuropathol (2013) 1.41
Mitochondrial dysfunction and decrease in body weight of a transgenic knock-in mouse model for TDP-43. J Biol Chem (2014) 1.37
Cellular model of TAR DNA-binding protein 43 (TDP-43) aggregation based on its C-terminal Gln/Asn-rich region. J Biol Chem (2012) 1.08
TDP-43-induced death is associated with altered regulation of BIM and Bcl-xL and attenuated by caspase-mediated TDP-43 cleavage. J Biol Chem (2011) 1.08
The truncated C-terminal RNA recognition motif of TDP-43 protein plays a key role in forming proteinaceous aggregates. J Biol Chem (2013) 1.05
Neurodegenerative models in Drosophila: polyglutamine disorders, Parkinson disease, and amyotrophic lateral sclerosis. Neurobiol Dis (2010) 1.02
On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and without dementia. Prog Neurobiol (2011) 0.95
Genetic strategies to study TDP-43 in rodents and to develop preclinical therapeutics for amyotrophic lateral sclerosis. Eur J Neurosci (2011) 0.88
Rodent models of TDP-43 proteinopathy: investigating the mechanisms of TDP-43-mediated neurodegeneration. J Mol Neurosci (2011) 0.87
Aberrant assembly of RNA recognition motif 1 links to pathogenic conversion of TAR DNA-binding protein of 43 kDa (TDP-43). J Biol Chem (2013) 0.86
The crystal structure of TDP-43 RRM1-DNA complex reveals the specific recognition for UG- and TG-rich nucleic acids. Nucleic Acids Res (2014) 0.86
ALS spinal neurons show varied and reduced mtDNA gene copy numbers and increased mtDNA gene deletions. Mol Neurodegener (2010) 0.84
Inhibition of TDP-43 aggregation by nucleic acid binding. PLoS One (2013) 0.83
Characterization of a series of 4-aminoquinolines that stimulate caspase-7 mediated cleavage of TDP-43 and inhibit its function. Biochimie (2012) 0.82
TARDBP mutations are not a frequent cause of ALS in Finnish patients. Acta Myol (2012) 0.82
Drosophila Answers to TDP-43 Proteinopathies. J Amino Acids (2012) 0.81
The influence of pathological mutations and proline substitutions in TDP-43 glycine-rich peptides on its amyloid properties and cellular toxicity. PLoS One (2014) 0.80
TDP-43 identified from a genome wide RNAi screen for SOD1 regulators. PLoS One (2012) 0.78
Transcription factors expressed in olfactory bulb local progenitor cells revealed by genome-wide transcriptome profiling. Mol Cell Neurosci (2010) 0.76
Targeting TDP-43 phosphorylation by Casein Kinase-1δ inhibitors: a novel strategy for the treatment of frontotemporal dementia. Mol Neurodegener (2016) 0.75
TDP-43 as a possible biomarker for frontotemporal lobar degeneration: a systematic review of existing antibodies. Acta Neuropathol Commun (2015) 0.75
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science (2006) 27.96
The Microprocessor complex mediates the genesis of microRNAs. Nature (2004) 17.70
TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science (2008) 14.09
Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science (2009) 13.45
Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science (2009) 12.99
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature (2006) 11.59
hnRNP proteins and the biogenesis of mRNA. Annu Rev Biochem (1993) 11.44
TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun (2006) 10.69
TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet (2008) 9.51
Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature (2006) 9.31
The RNA recognition motif, a plastic RNA-binding platform to regulate post-transcriptional gene expression. FEBS J (2005) 6.72
Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol (2007) 6.58
TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann Neurol (2007) 5.98
TDP-43 A315T mutation in familial motor neuron disease. Ann Neurol (2008) 5.58
TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol (2008) 5.33
hnRNP complexes: composition, structure, and function. Curr Opin Cell Biol (1999) 5.27
Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. EMBO J (2001) 5.23
Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. J Virol (1995) 5.18
TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol (2007) 5.02
Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9. J Biol Chem (2001) 4.87
Retracted DEAD-box RNA helicase subunits of the Drosha complex are required for processing of rRNA and a subset of microRNAs. Nat Cell Biol (2007) 4.45
A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain (2009) 4.40
Functional multivesicular bodies are required for autophagic clearance of protein aggregates associated with neurodegenerative disease. J Cell Biol (2007) 4.30
TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A (2009) 4.18
TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail: an important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing. J Biol Chem (2005) 3.99
Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol (2009) 3.73
Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet (2008) 3.66
Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc Natl Acad Sci U S A (2009) 3.65
Global mapping of the topography and magnitude of proteolytic events in apoptosis. Cell (2008) 3.64
Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. J Biol Chem (2008) 3.56
Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol (2007) 3.55
Progranulin mediates caspase-dependent cleavage of TAR DNA binding protein-43. J Neurosci (2007) 3.52
Structural diversity and functional implications of the eukaryotic TDP gene family. Genomics (2004) 3.51
A yeast TDP-43 proteinopathy model: Exploring the molecular determinants of TDP-43 aggregation and cellular toxicity. Proc Natl Acad Sci U S A (2008) 3.46
Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43. Acta Neuropathol (2007) 3.44
Human, Drosophila, and C.elegans TDP43: nucleic acid binding properties and splicing regulatory function. J Mol Biol (2005) 3.33
TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J Biol Chem (2009) 3.29
Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol (2008) 3.13
TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. J Neuropathol Exp Neurol (2007) 2.97
Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol (2008) 2.96
TDP-43 mutation in familial amyotrophic lateral sclerosis. Ann Neurol (2008) 2.92
TDP-43, the signature protein of FTLD-U, is a neuronal activity-responsive factor. J Neurochem (2007) 2.91
Structural determinants of the cellular localization and shuttling of TDP-43. J Cell Sci (2008) 2.79
Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol (2009) 2.76
TDP43 is a human low molecular weight neurofilament (hNFL) mRNA-binding protein. Mol Cell Neurosci (2007) 2.75
Expression of TDP-43 C-terminal Fragments in Vitro Recapitulates Pathological Features of TDP-43 Proteinopathies. J Biol Chem (2009) 2.60
TDP-43 regulates retinoblastoma protein phosphorylation through the repression of cyclin-dependent kinase 6 expression. Proc Natl Acad Sci U S A (2008) 2.58
TDP-43 is recruited to stress granules in conditions of oxidative insult. J Neurochem (2009) 2.57
Depletion of TDP 43 overrides the need for exonic and intronic splicing enhancers in the human apoA-II gene. Nucleic Acids Res (2005) 2.55
The RNA binding protein TLS is translocated to dendritic spines by mGluR5 activation and regulates spine morphology. Curr Biol (2005) 2.53
Depletion of TDP-43 affects Drosophila motoneurons terminal synapsis and locomotive behavior. FEBS Lett (2009) 2.48
Enrichment of C-terminal fragments in TAR DNA-binding protein-43 cytoplasmic inclusions in brain but not in spinal cord of frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Am J Pathol (2008) 2.41
Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies. Brain Res (2007) 2.38
Knockdown of transactive response DNA-binding protein (TDP-43) downregulates histone deacetylase 6. EMBO J (2009) 2.37
Structural insights into TDP-43 in nucleic-acid binding and domain interactions. Nucleic Acids Res (2009) 2.37
Caspase-specific and nonspecific in vivo protein processing during Fas-induced apoptosis. Nat Methods (2005) 2.33
TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration. Ann Neurol (2009) 2.30
TDP-43 is deposited in the Guam parkinsonism-dementia complex brains. Brain (2007) 2.25
Truncation and pathogenic mutations facilitate the formation of intracellular aggregates of TDP-43. Hum Mol Genet (2009) 2.23
Atypical frontotemporal lobar degeneration with ubiquitin-positive, TDP-43-negative neuronal inclusions. Brain (2008) 2.17
Characterization of an RNA granule from developing brain. Mol Cell Proteomics (2005) 2.07
High frequency of TARDBP gene mutations in Italian patients with amyotrophic lateral sclerosis. Hum Mutat (2009) 2.05
TDP-43-negative FTLD-U is a significant new clinico-pathological subtype of FTLD. Acta Neuropathol (2008) 2.02
TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without SOD1 gene mutation. Acta Neuropathol (2007) 2.01
Contribution of TARDBP mutations to sporadic amyotrophic lateral sclerosis. J Med Genet (2008) 2.00
Higher order arrangement of the eukaryotic nuclear bodies. Proc Natl Acad Sci U S A (2002) 1.99
TDP-43 overexpression enhances exon 7 inclusion during the survival of motor neuron pre-mRNA splicing. J Biol Chem (2008) 1.98
TARDBP variation associated with frontotemporal dementia, supranuclear gaze palsy, and chorea. Mov Disord (2009) 1.95
A reassessment of the neuropathology of frontotemporal dementia linked to chromosome 3. J Neuropathol Exp Neurol (2007) 1.95
Pathological TDP-43 in parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam. Acta Neuropathol (2007) 1.91
Evaluation of subcortical pathology and clinical correlations in FTLD-U subtypes. Acta Neuropathol (2009) 1.89
Missense mutations in the progranulin gene linked to frontotemporal lobar degeneration with ubiquitin-immunoreactive inclusions reduce progranulin production and secretion. J Biol Chem (2007) 1.87
A novel CpG-free vertebrate insulator silences the testis-specific SP-10 gene in somatic tissues: role for TDP-43 in insulator function. J Biol Chem (2007) 1.83
Two German kindreds with familial amyotrophic lateral sclerosis due to TARDBP mutations. Arch Neurol (2008) 1.78
Functional mapping of the interaction between TDP-43 and hnRNP A2 in vivo. Nucleic Acids Res (2009) 1.77
Divergent patterns of cytosolic TDP-43 and neuronal progranulin expression following axotomy: implications for TDP-43 in the physiological response to neuronal injury. Brain Res (2008) 1.77
Mutation within TARDBP leads to frontotemporal dementia without motor neuron disease. Hum Mutat (2009) 1.77
Proteolytic processing of TAR DNA binding protein-43 by caspases produces C-terminal fragments with disease defining properties independent of progranulin. J Neurochem (2009) 1.76
Abnormal phosphorylation of Ser409/410 of TDP-43 in FTLD-U and ALS. FEBS Lett (2008) 1.76
Frontotemporal dementia and amyotrophic lateral sclerosis-associated disease protein TDP-43 promotes dendritic branching. Mol Brain (2009) 1.65
TDP-43 pathologic lesions and clinical phenotype in frontotemporal lobar degeneration with ubiquitin-positive inclusions. Arch Neurol (2007) 1.57
Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions visualized with ubiquitin-binding protein p62 immunohistochemistry. J Neuropathol Exp Neurol (2008) 1.55
TDP-43 pathology in familial frontotemporal dementia and motor neuron disease without Progranulin mutations. Brain (2007) 1.55
Frontotemporal lobar degeneration with ubiquitin-positive, but TDP-43-negative inclusions. Acta Neuropathol (2008) 1.49
Intracellular trafficking of RNA in neurons. Traffic (2006) 1.47
Characterization of alternative isoforms and inclusion body of the TAR DNA-binding protein-43. J Biol Chem (2009) 1.44
TDP-43 depletion induces neuronal cell damage through dysregulation of Rho family GTPases. J Biol Chem (2009) 1.44
Mimicking aspects of frontotemporal lobar degeneration and Lou Gehrig's disease in rats via TDP-43 overexpression. Mol Ther (2009) 1.42
Cell cycle molecules define a pathway required for neuron death in development and disease. Biochim Biophys Acta (2006) 1.35
Neuronal inclusion protein TDP-43 has no primary genetic role in FTD and ALS. Neurobiol Aging (2008) 1.31
Pallidonigral TDP-43 pathology in Perry syndrome. Parkinsonism Relat Disord (2008) 1.29
Cycling at the interface between neurodevelopment and neurodegeneration. Cell Death Differ (2002) 1.28
Phosphorylated and ubiquitinated TDP-43 pathological inclusions in ALS and FTLD-U are recapitulated in SH-SY5Y cells. FEBS Lett (2008) 1.21
TDP-43 gene analysis in frontotemporal lobar degeneration. Neurosci Lett (2007) 1.20
TARDBP (TDP-43) sequence analysis in patients with familial and sporadic ALS: identification of two novel mutations. Eur J Neurol (2009) 1.18
A90V TDP-43 variant results in the aberrant localization of TDP-43 in vitro. FEBS Lett (2008) 1.17
Neuronal death in amyotrophic lateral sclerosis is apoptosis: possible contribution of a programmed cell death mechanism. J Neuropathol Exp Neurol (1999) 1.17
TDP-43 M311V mutation in familial amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2009) 1.17
TAR DNA-binding protein 43 immunohistochemistry reveals extensive neuritic pathology in FTLD-U: a midwest-southwest consortium for FTLD study. J Neuropathol Exp Neurol (2008) 1.16
Caspase-cleaved TAR DNA-binding protein-43 is a major pathological finding in Alzheimer's disease. Brain Res (2008) 1.16
Bioassay of pesticides and industrial chemicals for tumorigenicity in mice: a preliminary note. J Natl Cancer Inst (1969) 3.33
MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology (2008) 2.69
REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology (2010) 2.50
Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol (2001) 2.50
Frontotemporal brain sagging syndrome: an SIH-like presentation mimicking FTD. Neurology (2011) 2.27
alpha-Synuclein shares physical and functional homology with 14-3-3 proteins. J Neurosci (1999) 2.25
Sporadic adult-onset leukoencephalopathy with neuroaxonal spheroids mimicking cerebral MS. Neurology (2008) 1.78
Imaging correlates of pathology in corticobasal syndrome. Neurology (2010) 1.71
Gray and white matter water diffusion in the syndromic variants of frontotemporal dementia. Neurology (2010) 1.57
Long-term cognitive outcomes following out-of-hospital cardiac arrest: a population-based study. Neurology (2011) 1.51
The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J Neurosci (2000) 1.51
Voxel-based morphometry patterns of atrophy in FTLD with mutations in MAPT or PGRN. Neurology (2009) 1.48
Parkinsonism and tardive antecollis in frontotemporal dementia--increased sensitivity to newer antipsychotics? Eur J Neurol (2008) 1.47
Biological role of D-amino acid oxidase and D-aspartate oxidase. Effects of D-amino acids. J Biol Chem (1993) 1.37
Involvement of D-aspartic acid in the synthesis of testosterone in rat testes. Life Sci (1996) 1.28
The alpha-synuclein gene in multiple system atrophy. J Neurol Neurosurg Psychiatry (2006) 1.25
Does TDP-43 type confer a distinct pattern of atrophy in frontotemporal lobar degeneration? Neurology (2010) 1.25
Alpha-synuclein pathology in the spinal cords of neurologically asymptomatic aged individuals. Neurology (2006) 1.24
SEPT5_v2 is a parkin-binding protein. Brain Res Mol Brain Res (2003) 1.17
Atrophy patterns in IVS10+16, IVS10+3, N279K, S305N, P301L, and V337M MAPT mutations. Neurology (2009) 1.16
Pathologically confirmed corticobasal degeneration presenting with visuospatial dysfunction. Neurology (2003) 1.13
Frontotemporal lobar degeneration with ubiquitin-only-immunoreactive neuronal changes: broadening the clinical picture to include progressive supranuclear palsy. Brain (2004) 1.12
Characterization of DCTN1 genetic variability in neurodegeneration. Neurology (2009) 1.11
Atrophy of superior cerebellar peduncle in progressive supranuclear palsy. Neurology (2003) 1.08
Further study on the specificity of D-amino acid oxidase and D-aspartate oxidase and time course for complete oxidation of D-amino acids. Comp Biochem Physiol B (1993) 1.07
Brain metal concentrations in chronic liver failure patients with pallidal T1 MRI hyperintensity. Neurology (2006) 1.01
Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine. Neurology (2005) 1.01
Altered functional connectivity in asymptomatic MAPT subjects: a comparison to bvFTD. Neurology (2011) 0.99
Transfected synphilin-1 forms cytoplasmic inclusions in HEK293 cells. Brain Res Mol Brain Res (2001) 0.98
Dopamine agonist-triggered pathological behaviors: surveillance in the PD clinic reveals high frequencies. Parkinsonism Relat Disord (2011) 0.94
Trajectories of brain and hippocampal atrophy in FTD with mutations in MAPT or GRN. Neurology (2011) 0.93
Neuropsychological profiles of manganese neurotoxicity. Eur J Neurol (2006) 0.92
Midbrain atrophy is not a biomarker of progressive supranuclear palsy pathology. Eur J Neurol (2013) 0.92
Coexistent Lewy body disease in a case of "visual variant of Alzheimer's disease". J Neurol Neurosurg Psychiatry (2003) 0.90
Free D-amino acids in human cerebrospinal fluid of Alzheimer disease, multiple sclerosis, and healthy control subjects. Mol Chem Neuropathol (1995) 0.88
Mapping the onset and progression of atrophy in familial frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry (2005) 0.88
Single dose of palonosetron plus dexamethasone to control nausea, vomiting and to warrant an adequate food intake in patients treated with highly emetogenic chemotherapy (HEC). Preliminary results. Support Care Cancer (2009) 0.87
Predicting survival in frontotemporal dementia with motor neuron disease. Neurology (2011) 0.86
Neuroimaging comparison of primary progressive apraxia of speech and progressive supranuclear palsy. Eur J Neurol (2012) 0.84
Late-onset frontotemporal dementia associated with progressive supranuclear palsy/argyrophilic grain disease/Alzheimer's disease pathology. Neurocase (2005) 0.83
Clinical and imaging features of Othello's syndrome. Eur J Neurol (2011) 0.83
Co-association of parkin and alpha-synuclein. Neuroreport (2001) 0.82
Regional decreases of free D-aspartate levels in Alzheimer's disease. Neurosci Lett (1998) 0.82
Identification and characterization of the human parkin gene promoter. J Neurochem (2001) 0.81
Quantification of D-aspartate in normal and Alzheimer brains. Neurosci Lett (1992) 0.81
Brain atrophy over time in genetic and sporadic frontotemporal dementia: a study of 198 serial magnetic resonance images. Eur J Neurol (2015) 0.80
Clinical and imaging characterization of progressive spastic dysarthria. Eur J Neurol (2013) 0.79
Amyloid burden correlates with cognitive decline in Alzheimer's disease presenting with aphasia. Eur J Neurol (2013) 0.79
Targeting heat shock proteins in tauopathies. Curr Alzheimer Res (2010) 0.79
Amiodarone-associated neuromyopathy: a report of four cases. Eur J Neurol (2012) 0.79
Voxel-based morphometry in patients with obsessive-compulsive behaviors in behavioral variant frontotemporal dementia. Eur J Neurol (2012) 0.79
Presence of D-alanine in proteins of normal and Alzheimer human brain. Brain Res (1992) 0.78
Varied electrophysiologic patterns in spinocerebellar ataxia type 2. Eur J Neurol (2006) 0.75
Compulsive urination as a presenting symptom of frontotemporal dementia. Eur J Neurol (2007) 0.75
Sudden behavioral disturbance in a man with a lesion in the nucleus accumbens. J Neurol (2008) 0.75
Improved method for hydrolyzing proteins and peptides without inducing racemization and for determining their true D-amino acid content. Anal Biochem (1993) 0.75
25-year-old woman with incoordination and decreased balance. Mayo Clin Proc (2001) 0.75
The corticobasal syndrome triggered by central pontine myelinolysis. Eur J Neurol (2006) 0.75
Hippocampal sclerosis in a case of Alzheimer's disease-like dementia with late onset intractable epilepsy. Eur J Neurol (2003) 0.75